LA JOLLA CANCER RESEARCH FOUNDATION

ANIMAL USAGE FORM

AUF 1413

PLEASE TYPE OR PRINT

1. PRINCIPAL INVESTIGATOR: WAYNE A. BORDER, M.D. | OFFICE PHONE: 226 | HOME/EMERGENCY PHONE: (714) 770-4602
2. OTHER INVESTIGATOR: LUCIA LANGUINO, Ph.D. | 230 | 539-0609
3. SENIOR TECHNICIAN:
4. PROJECT TITLE: ANTI-HUMAN TGFβ CYCLIZED PEPTIDE
5. GRANT NUMBER, IF ANY: 250200 | NEW: X | RENEWAL: | PILOT: | PROJECT NUMBER:
6. START DATE: | END DATE: | QUANTITY: | MICE: | RATS: | RABBITS: 2 | GPs: | OTHER (SPECIFY):
7. PROJECT GOAL (SEE INSTRUCTIONS)

To produce quantities of anti-human TGFβ cyclized peptide for use in kidney disease research.

8. RATIONALE (SEE INSTRUCTIONS)

Rabbits produce high quality antiserum which can be used for identification of human TGFβ in tissue samples and in vitro assays to study progression of kidney injury.

9. DESCRIBE USE OF ANIMALS (SEE INSTRUCTIONS)

All injections/bleedings to be performed by animal care facility personnel.

1. Pre-bleeding 20 ml from ear vein .
2. Inject 500 μg TGFβ cyclized purified peptide (0.5 ml antigen in PBS + 0.5 ml FCA) subcutaneously in 2 sites.
3. After one month, boost with 125 μg antigen (0.25 ml antigen in PBS + 0.25 ml incomple adjuvant) subcutaneously, 2 sites.
4. After 10 days, bleed 50 ml from alternating ear veins 3 times.
5. Repeat steps 3-4 at 4-6 week intervals.

IACUC ANIMAL RESEARCH COMMITTEE
PO... PERSONNEL ... ALL ANIMAL ... INJECTIONS ... AND/OR ... IN THIS RESEARCH PROTOCOL

10. PAIN LEVEL: A [X] B [ ] C [ ] (IF B OR C READ INSTRUCTIONS. PROVIDE DESCRIPTION OR JUSTIFICATION HERE)

CONFIDENTIAL

11. EUTHANASIA (SEE INSTRUCTIONS)

DURING PROJECT		METHOD OR TECHNIQUE	CO_2		CERV. DISLOC.		RETAIN CARCASS(ES) FOR PI: YES
END OF PROJECT	X		O.D.	X	OTHER (SPECIFY)		NO X

12. SIGNATURES

PI: WA Borde — DATE:

AF MGR — DATE:

U2 05334

DISTRIBUTION: WHITE TO FILE CANARY TO PI PINK - EXTR.

FORM AF 286 REV 3/96

EXHIBIT A